ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2009
Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Racial, ethnic, sex, and age representation in clinical trials of radiopharmaceutical tumor therapy: a systematic review and meta-analysis.BMC cancer · 2025Pooled it
- Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: report of the NRG Oncology RTOG 0517 trial.Annals of nuclear medicine · 2018Trial
- Targeting the interleukin-11 receptor α in metastatic prostate cancer: A first-in-man study.Cancer · 2015Trial
- Reply to 'Single high dose versus repeated bone-targeted radionuclide therapy'.European journal of nuclear medicine and molecular imaging · 2018Article
- Efficacy and safety ofSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2018Article
- Phase I/II trials ofEuropean journal of nuclear medicine and molecular imaging · 2017Article
- The role of radiation therapy in the treatment of metastatic castrate-resistant prostate cancer.Therapeutic advances in urology · 2015Review
- Recent advances in bone-targeted therapies of metastatic prostate cancer.Cancer treatment reviews · 2014Review
- Article
- Beyond Palliation: Therapeutic Applications ofClinical & experimental pharmacology · 2013Article
- Optimal bone health management strategies in patients with prostate cancer.Indian journal of urology : IJU : journal of the Urological Society of India · 2013Article
- Targeting bone physiology for the treatment of metastatic prostate cancer.Clinical advances in hematology & oncology : H&O · 2013Review
- Bone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms.Prostate cancer · 2013Review
- Novel approaches in the pharmacotherapy of skeletal-related events in metastatic castrate-resistant prostate cancer.Anticancer research · 2012Review
- Therapeutic strategies for bone metastases and their clinical sequelae in prostate cancer.Current treatment options in oncology · 2012Review
- A phase I study of combined docetaxel and repeated high activity 186Re-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial).European journal of nuclear medicine and molecular imaging · 2011Article
- Optimal management of bone metastases in prostate cancer.Current oncology reports · 2011Article
- Bone metastasis in prostate cancer: emerging therapeutic strategies.Nature reviews. Clinical oncology · 2011Review
- Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer.Clinical advances in hematology & oncology : H&O · 2010Review
- Castration-resistant prostate cancer: new science and therapeutic prospects.Therapeutic advances in medical oncology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSamarium-153 ((153)Sm) lexidronam is a bone-targeting radiopharmaceutical with a short physical half-life and a favorable toxicity profile. We evaluated the safety and feasibility of a concurrent combination of weekly docetaxel with repeated (153)Sm-lexidronam in patients with castration-resistant prostate cancer (CRPC). PATIENTS AND
methodsA conventional 3 + 3 dose-escalation design was used for this study. Patients were treated in three cohorts comprising two cycles of weekly docetaxel at 25, 30, and 35 mg/m(2), respectively, on days 1, 8, and 15 of a 28-day cycle in combination with (153)Sm (1 mCi/kg) on day 1. Unacceptable hematologic toxicity (UHT) was defined as more than 7 days delay in therapy for inadequate counts: an absolute neutrophil count (ANC) more than 1,000/microL and platelets more than 70,000/microL were required at days 8 and 15 and ANC more than 1,500/microL and platelets more than 100,000/microL were required at cycle 2, day 1. If counts had not recovered by day 56 of either combination cycle, UHT was declared.
resultsEighteen patients were treated in three cohorts. Two patients in separate cohorts experienced UHT; the maximum-tolerated dose for this regimen was not reached. The median interval between (153)Sm doses was 35 days (range, 27 to 57 days). The only significant toxicity was mild, transient myelosuppression. Five patients (28%) experienced grade 3 hematologic toxicity. There were no grade > or = 4 hematologic or nonhematologic toxicities.
conclusionTwo dosing cycles consisting of weekly docetaxel and monthly (153)Sm-lexidronam were well tolerated and feasible in this CRPC population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.